31 mai 2012

Receptor

Bevacizumab (Avastin ○ R) Bevacizumab (Avastin ○ R, rhuMAb-VEGF, Genetech Inc.) Receptor humanized antibody against vascular endothelial growth factor (VEGF), is currently the treatment of colorectal cancer and breast cancer stage Ⅲclinical studies. VEGF regulate angiogenesis, regulation of vascular permeability and function of anti-apoptotic effects on endothelial cells of neovascularization. Bevacizum ˉ ab monotherapy tumor has made a significant therapeutic effect, can also enhance anti-tumor efficacy of chemotherapy. In the... [Lire la suite]
Posté par tnfalpha à 16:42 - Commentaires [0] - Permalien [#]